[Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy].
Kobayashi
Hiroyuki
H
h_kobayashi@lilly.com
Hamaya
Etsuro
E
D000818:Animals; D015519:Bone Density / Q000187:drug effects; D016723:Bone Remodeling / Q000187:drug effects; D001862:Bone Resorption / Q000188:drug therapy; D001842:Bone and Bones / Q000378:metabolism; D001943:Breast Neoplasms / Q000517:prevention & control; D018849:Controlled Clinical Trials as Topic; D003327:Coronary Disease / Q000517:prevention & control; D005260:Female; D050723:Fractures, Bone / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D011960:Receptors, Estrogen / Q000378:metabolism; D020845:Selective Estrogen Receptor Modulators / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D020521:Stroke / Q000517:prevention & control; D014157:Transcription Factors / Q000502:physiology
D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D014157:Transcription Factors; D020849:Raloxifene Hydrochloride